RMD – UBS rates the stock as Neutral

UBS has analysed the current penetration of the US obstructive sleep apnoea (OSA) market and assessed the sustainability of new patient flow generator set-up growth.

While the broker acknowledges reaching a definitive conclusion is difficult, the base case forecast suggests the US is around 60% penetrated. Assuming flow generator volume growth of 5% over the forecast period, full saturation is reached in FY28. However, this is extended out to FY36 when using a figure for disease prevalence of 20%.

UBS reveals feedback from US sleep physicians suggests no sign of slowdown in new patient diagnosis, with obesity and ageing being the key drivers.

The broker anticipates a robust 4Q20 result and forecasts sales growth of of 15% and non-GAAP EPS of US$1.33.

Neutral rating maintained. Target is raised to US$200 from US$183.

Sector: Health Care Equipment & Services.

Current Price is $29.27. Target price not assessed.

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →